2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL
Charter Amendment Approved; Authorized Shares Increased to 200 Million
Reports First Quarter 2026 Financial Results and Provides Business Update
Unlocking Life Changing Therapies March 2026
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD, Other Events
Board Approves Amended Employment Agreements for Executive Officers
Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Correspondence
Submission Upload